Editas Medicine announces poster presentations at ESGCT 33rd Annual Congress and investor conference participation

Editas Medicine announces poster presentations at ESGCT 33rd Annual Congress and investor conference participation
Editas set for ESGCT Congress

Editas Medicine has revealed plans to present scientific posters at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress.

The company also announced its participation in an upcoming investor conference. No further details have been provided in the announcement.

Earlier this year, Editas Medicine secured approval to launch its first in human clinical trial of EDIT-401 for hyperlipidemia patients, according to company filings. The move marked a key step as the firm advances its gene editing therapies. The company continues to announce new research and investor engagements.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.